CVS HEALTH Corp — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
CVS Health reported Q3 2026 revenues of $108.4B (up 5.4% YoY) with GAAP diluted EPS of $1.68 and Adjusted EPS of $2.09. The company raised full-year 2026 guidance: GAAP diluted EPS to at least $6.98 (from $6.84–$7.04 range), Adjusted EPS to at least $8.20 (from $7.90–$8.10), and cash flow from operations to at least $15.5B (from at least $11.5B). Improvements driven by Health Care Benefits segment (MBR improved to 91.3% from 92.8%) and Pharmacy & Consumer Wellness segment strength.
Why this rating
Solid Q3 operational beat and raised full-year guidance are positive, but magnitude (~0.5% to 1.3% EPS lift relative to prior midpoint) is modest for $86.4B market-cap company. Reflects execution, not transformational change.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.